• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2015.10038

Development of a pharmacetical anticancer gel based on doxorubicin and silicone nanotechnology

[Clinical Pharmacology]
Igor Bazikov; Elena Chekrygina; Inna Klimanovich; Alexander Maltsev;

Developed a gel based on pharmacological niosomes silicone nature incorporated with the anticancer drug – doxorubicin at 5 mg/ml to enhance the efficacy of cancer treatment. Using prototype gel doxorubicin niosomes composition provides greater bioavailability of the antibiotic and significantly prolongs its retention time in blood concentrations. Even 48 hours after gel application prototype drug concentration in the blood exceeds control values three times. The transdermal route of administration of doxorubicin can reduce the cardiotoxic effect of the drug, dyspeptic reactions, reduce the likelihood of necrosis at the injection site, which significantly extends the use of the drug among patients with heart failure, diseases of the gastrointestinal tract.

Download

References:
1. Bazikov I. A. Method transdermal transport of the active substances using niosomes based on PEG-12 dimethicone. RF patent number 2539396 on 12/02/2014.
2. Basso U., Roma, A., Brunello, A., Falci, C., Fiduccia, P., Banzato, A., Monfardini S. Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70years). Journal of Geriatric Oncology 2013;4(4):340-345. doi:10.1016/j.jgo.2013.07.004
3. Batist G., Harris L., Azarnia N. et al. Improved anti-tumor response rate with decreased cardiotoxicity of nonpegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006;17:587-595.
4. Goel P. N., Gude R. P. Delineating the anti-metastatic potential of pentoxifylline in combination with liposomal doxorubicin against breast cancer cells. Biomedicine & Pharmacotherapy 2014;68(2):191-200. doi:10.1016/j.biopha.2013.11.003
5. Farrukh A., Munagala R., Jeyabalan J., Vadhanam M. V. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Letters 2013;334(1), 133-141. doi:10.1016/j.canlet.2013.02.032
6. Guidelines for preclinical studies of drugs. Part One / ed. AN Mironov, publishing house: Grief and K, Moscow, 2012.
7. Harris L., Batist G., Belt R. et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25-36. doi:10.1002/cncr.10201
8. Judson I., Verweij J., Glderblom H. et al. Doxorubicin alone versus intensifi ed doxorubicin plus ifosfamide for fi rst-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014;15:415–423.
9. Le Cesne A., Blay J. Y., Judson I., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576–84.
10. Martin-Broto J., Lopez-Pousa A., Garcai del Muro X., et al. Randomized phase II trial of doxorubicin vs. trabectedin plus doxorubicin in first line treatment of patients with advanced nonresectable or metastatic soft tissue sarcomas: a Spanish Group for Sarcoma Research (GEIS) study. Eur J Cancer 2013;49:s3800.
11. Palmieri C., Misra V., Januszewski A., Yosef H., Ashford R., Keary I., Davidson N. Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer. Clinical Breast Cancer 2014;14(2):85-93. doi:10.1016/j.clbc.2013.10.011
12. Pautier P., Floquet A., Chevreau C., Penel N., Guillemet C., Delcambre C., Duffaud F. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. The Lancet Oncology, 2015;16(4),457-464. doi:10.1016/S1470-2045(15)70070-7

Keywords: doxorubicin, niosomes, niosomal gel, skin cancer